{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"Clinical response for platelets was assessed as the number of participants achieving a hematological improvement - platelets (HI-P). Participants will be characterized and stratified as platelets \\< or ≥ 20 x 10\\^9/L, with response defined as follows.\n\n* \\< 20 x 10\\^9/L = increase in platelets from \\< 20 x 10\\^9/L to \\> 20 x 10\\^9/L AND by ≥ 100%\n* ≥ 20 x 10\\^9/L = absolute increase in platelets of 30 x 10\\^9/L The outcome will be reported as the number of participants that achieve the response, a number without dispersion.","groups":[{"description":"Participants in this dose-escalation cohort self-administered enasidenib mesylate orally at a dose of 100 mg once daily.","id":"OG000","title":"Enasidenib Mesylat 100 mg"},{"description":"Participants in this dose-escalation cohort self-administered enasidenib mesylate orally at a dose of 200 mg once daily.","id":"OG001","title":"Enasidenib Mesylat 200 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"8 weeks","title":"Clinical Response: Hematological Improvement - Platelets (HI-P)","type":"SECONDARY","unitOfMeasure":"Participants"}